Cargando…

PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study

PURPOSE: Our study was to evaluate the influence of positive lymph nodes ratio (PLNR) on survival for patients with pathological stage IIIA-N2 non-small cell lung cancer (NSCLC) after receiving postoperative radiotherapy (PORT). PATIENTS AND METHODS: The chi-squared test was used to compare the pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shang, Xiaoling, Li, Zhenxiang, Lin, Jiamao, Wang, Haiyong, Wang, Zhehai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152602/ https://www.ncbi.nlm.nih.gov/pubmed/30271204 http://dx.doi.org/10.2147/CMAR.S173856

Ejemplares similares

A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC
por: Shang, Xiaoling, et al.
Publicado: (2019)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
por: Zhang, Chenxing, et al.
Publicado: (2020)

Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study
por: Shan, Qinge, et al.
Publicado: (2020)

Incorporating the Number of PLN into the AJCC Stage Could Better Predict the Survival for Patients with NSCLC: A Large Population-Based Study
por: Shang, Xiaoling, et al.
Publicado: (2020)

Radiotherapy may improve survival of ES-SCLC with distant metastasis only for patients with one metastatic site: A population-based study
por: Shang, Xiaoling, et al.
Publicado: (2020)

A Novel Nomogram including AJCC Stages Could Better Predict Survival for NSCLC Patients Who Underwent Surgery: A Large Population-Based Study
por: Shang, Xiaoling, et al.
Publicado: (2020)

Surgical intervention may be a therapeutic option for NSCLC patients with AJCC stage IV: a large population-based study
por: Wang, Haiyong, et al.
Publicado: (2018)

Molecular subtyping of small‐cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies
por: Wang, Haiyong, et al.
Publicado: (2022)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
por: Lin, Jiamao, et al.
Publicado: (2021)

Surgery as a Potential Treatment Option for Patients With Stage III Small-Cell Lung Cancer: A Propensity Score Matching Analysis
por: Zhang, Chenyue, et al.
Publicado: (2019)

The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients
por: Wang, Yukun, et al.
Publicado: (2023)

Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinoma
por: Kou, Peisi, et al.
Publicado: (2019)

Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types
por: Zhang, Chenyue, et al.
Publicado: (2020)

Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?
por: Weder, Walter, et al.
Publicado: (2021)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
por: Zhang, Lijuan, et al.
Publicado: (2021)

Commentary: A new PORT in the stage IIIA N2 non–small cell lung cancer storm
por: Ashbrook, Matthew J., et al.
Publicado: (2021)

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
por: Brascia, Debora, et al.
Publicado: (2020)

The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study
por: Duan, Hongxia, et al.
Publicado: (2020)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Preoperative radiation may improve the outcomes of resectable IIIA/N2 non‐small‐cell lung cancer patients: A propensity score matching‐based analysis from surveillance, epidemiology, and end results database
por: Chen, Dawei, et al.
Publicado: (2018)

A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab
por: Shang, Xiaoling, et al.
Publicado: (2021)

Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database
por: Wang, Xia, et al.
Publicado: (2021)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC
por: Agrawal, Vishesh, et al.
Publicado: (2017)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8(+) T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma
por: Zhang, Chenyue, et al.
Publicado: (2022)

Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study
por: Casiraghi, Monica, et al.
Publicado: (2021)

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy
por: Yang, Hui, et al.
Publicado: (2021)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

Relationship between tumor size and metastatic site in patients with stage IV non-small cell lung cancer: A large SEER-based study
por: Shan, Qinge, et al.
Publicado: (2019)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers
por: Kilvaer, Thomas K., et al.
Publicado: (2015)

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Dan, Aravot, et al.
Publicado: (2019)

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
por: Garitaonaindia, Yago, et al.
Publicado: (2023)

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study
por: Shan, Qinge, et al.
Publicado: (2021)

The appropriate number of ELNs for lymph node negative breast cancer patients underwent MRM: a population-based study
por: Chi, Huiying, et al.
Publicado: (2017)

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Aravot, Dan, et al.
Publicado: (2019)

Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma
por: Li, Jia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6lo69jd5degk4jcq8gd5cqr8c4